Elevance Health, Inc. ELV
NYSEHealthcare servicesFinancials to Sep 30, 2026 · Updated Nov 11, 2026
Moat ranks
Balance sheet
| $B | Dec 31 | Sep 30 |
|---|---|---|
| Cash | 9.1 | 10.3 |
| Securities | 26.6 | 25.3 |
| Long-term securities | 0.0 | 1.2 |
| Restricted cash | 1.5 | 0.5 |
| Debt | 31.9 | 30.8 |
| Net cash | 3.9 | 6.1 |
| Equity | 43.9 | 44.7 |
- Debt / EBITDA
- 4.79×
- Debt / equity
- 0.69×
- Leases (12/31/25)
- $660M
- Diluted shares
- 218M
- Book value / share
- $205.34
- Price / book
- 2.1×
- Net cash / share
- $28.26
- Market cap
- $92.8B
- Enterprise value
- $86.7B
Per-share record
Key indicators
| Indicator | Latest | Vs year ago | Last 8 quarters |
|---|---|---|---|
| Revenue growth | 1.4% | -11.0 pts | |
| Operating margin | 2.3% | +0.0 pts | |
| FCF margin | 1.9% | +0.4 pts | |
| Capex / revenue | 0.5% | -0.2 pts | |
| Medical members | 44.9M | -1% | |
| Adjusted prescriptions | 82.6M | -3% | |
| Carelon Services consumers | 91.0M | -7% | |
| Benefit expense ratio | 90.6% | -0.7 pts | |
| Gross margin | – | – | – |
Margins and growth from reported quarters; company KPIs as reported in results releases.
About ELV
Elevance sells employer, individual and government health coverage, pharmacy benefits through CarelonRx, and clinical and administrative services through Carelon Services. Health Benefits supplies about 84% of external segment revenue.
- Concession License
BCBSA license agreements grant (largely) exclusive rights to use Blue Cross / Blue Shield names and marks in assigned territories.
- Brand Trust
The Blue brands give local recognition and access to an established national network.
- Data Workflow Lockin
Replacing claims adjudication, formulary data, pharmacy networks and member services requires a coordinated payer transition.
- Suite Bundling
Distribution advantage from selling PBM services to Elevance-affiliated health plans plus external clients; supports cross-sell with medical and other Carelon services.
- Nov 10, 2026
Elevance reaffirmed its 2026 EPS floors of $22.00 GAAP and $29.00 adjusted on November 10, with benefit expense ratio guidance of 90.2% plus or minus 50 basis points. This is a forecast, not a realized underwriting result. Source: https://www.sec.gov/Archives/edgar/data/1156039/000115603926000074/elv-20261110.htm
- Oct 1, 2026
Elevance announced its 2027 Medicare Advantage offerings, keeping local brands and coordinated services as its enrollment proposition for the new plan year.
- Sep 10, 2026
Elevance reaffirmed full-year earnings and medical-cost guidance, leaving the expected recovery dependent on premium repricing and claims performance.
- Jul 13, 2026
CMS closed the risk-adjustment enforcement process after required data corrections; the threatened sanctions were not imposed, but repayment obligations remained.
- Mar 31, 2026
Elevance appointed new government-business and Carelon leaders to improve clinical execution, financial oversight and coordination with the health plans.
Ownership
Go deeper on ELV
- Compare stock research toolsFundamentals, valuation and screening platforms for ELV.19 tools
- See ELV's price chartNo price chart here yet. See price history and indicators.17 tools
- Read ELV's earnings callsTranscripts and audio of results calls, with management's own words.15 tools
- Investing tool dealsCurrent discounts on research, charting and tracking tools.98 deals
On this page
Financial record
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | Trend | Change 2016–25 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Per share ($) | |||||||||||||
| Revenue | 316.53 | 336.22 | 348.62 | 400.36 | 479.23 | 561.75 | 644.95 | 721.74 | 760.03 | 886.58 | 927.53 | +12.1%/yr | |
| Cash flow | 12.20 | 15.63 | 14.49 | 23.28 | 42.03 | 33.89 | 34.59 | 33.96 | 24.94 | 19.10 | 34.91 | +5.1%/yr | |
| Earnings | 9.21 | 14.35 | 14.19 | 18.47 | 17.98 | 24.95 | 24.28 | 25.22 | 25.68 | 25.21 | 23.62 | +11.8%/yr | |
| Free cash flow | 10.02 | 12.67 | 9.91 | 19.15 | 38.01 | 29.49 | 29.85 | 28.50 | 19.54 | 14.13 | 29.94 | +3.9%/yr | |
| Capex | 2.18 | 2.95 | 4.57 | 4.14 | 4.01 | 4.40 | 4.74 | 5.46 | 5.39 | 4.97 | 4.97 | +9.6%/yr | |
| Dividends | 2.55 | 2.63 | 2.94 | 3.14 | 3.75 | 4.47 | 5.06 | 5.88 | 6.47 | 6.81 | 6.89 | +11.5%/yr | |
| Book value | 93.63 | 98.97 | 108.03 | 121.89 | 130.55 | 146.25 | 149.27 | 165.57 | 177.39 | 195.38 | 205.34 | +8.5%/yr | |
| Diluted shares (M) | 268 | 268 | 264 | 260 | 254 | 247 | 243 | 237 | 233 | 225 | 218 | -1.9%/yr | |
| Totals ($B) | |||||||||||||
| Revenue | 84.9 | 90.0 | 92.1 | 104.2 | 121.9 | 138.6 | 156.6 | 171.3 | 177.0 | 199.1 | 201.8 | +9.9%/yr | |
| Operating income | 4.6 | 4.0 | 5.1 | 5.7 | 6.0 | 7.1 | 7.5 | 7.6 | 7.3 | 6.6 | 4.9 | +4.0%/yr | |
| Net income | 2.5 | 3.8 | 3.8 | 4.8 | 4.6 | 6.2 | 5.9 | 6.0 | 6.0 | 5.7 | 5.1 | +9.7%/yr | |
| Free cash flow | 2.7 | 3.4 | 2.6 | 5.0 | 9.7 | 7.3 | 7.2 | 6.8 | 4.6 | 3.2 | 6.5 | +1.9%/yr | |
| Buybacks | 0.0 | 2.0 | 1.7 | 1.7 | 2.7 | 1.9 | 2.3 | 2.7 | 2.9 | 2.6 | 2.2 | – | |
| Dividends | 0.7 | 0.7 | 0.8 | 0.8 | 1.0 | 1.1 | 1.2 | 1.4 | 1.5 | 1.5 | 1.5 | +9.3%/yr | |
| Net cash | 7.3 | 5.3 | 3.3 | 6.0 | 10.5 | 10.1 | 10.2 | 11.2 | 3.4 | 3.9 | 6.1 | −$3.4B | |
| Margins & returns (%) | |||||||||||||
| Operating margin | 5.4 | 4.4 | 5.5 | 5.4 | 4.9 | 5.1 | 4.8 | 4.4 | 4.1 | 3.3 | 2.4 | -2.1 pts | |
| Net margin | 2.9 | 4.3 | 4.1 | 4.6 | 3.8 | 4.4 | 3.8 | 3.5 | 3.4 | 2.8 | 2.5 | -0.1 pts | |
| FCF margin | 3.2 | 3.8 | 2.8 | 4.8 | 7.9 | 5.2 | 4.6 | 3.9 | 2.6 | 1.6 | 3.2 | -1.6 pts | |
| ROIC | 20.5 | 15.0 | 16.0 | 17.5 | 21.0 | 21.8 | 22.9 | 21.5 | 15.3 | 13.1 | 9.9 | -7.5 pts | |
| Return on equity | 9.8 | 14.5 | 13.1 | 15.2 | 13.8 | 17.1 | 16.3 | 15.2 | 14.5 | 12.9 | 11.5 | +3.1 pts | |
| Stock pay % of revenue | 0.2 | 0.2 | 0.2 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | -0.1 pts | |
| Capex % of revenue | 0.7 | 0.9 | 1.3 | 1.0 | 0.8 | 0.8 | 0.7 | 0.8 | 0.7 | 0.6 | 0.5 | -0.1 pts | |
Change uses 2016 and 2025 only: compound annual growth for amounts, points for margins and returns, and the change in amount for net cash. A dash means no 2016 base. Trend shows the fiscal years.
Moat
Moat scorecard
- Strength
- Confidence
- Structure
- Oligopoly
- Durability
- durable
- Trajectory
- stable
- Pricing power
- moderate
- Health Benefits84.1%2 claims
- CarelonRx12.3%2 claims
- Carelon Services3.6%1 claim
Moat claims
- Applies to
- Health Benefits
- Confidence
- Durability
- durable
- Trajectory
- stableas of Oct 7, 2026
BCBSA license agreements grant (largely) exclusive rights to use Blue Cross / Blue Shield names and marks in assigned territories.
Blue brand licenses still cover 14 states, while the 80% local revenue requirement and capital standards remain; second Blue bids for selected national employers limit the exclusivity.
- Medical members44,882,000-1%
- Benefit expense ratio90.6%-0.7 pts
- BCBSA rule changes weakening exclusivity
- License termination from non-compliance or change-of-control constraints
- Antitrust/settlement changes enabling more second-bid competition for national accounts
- FilingElevance Health Form 10-K (FY ended 2025-12-31)Feb 6, 2026
- Applies to
- Health Benefits
- Confidence
- Durability
- durable
- Trajectory
- narrowingas of Oct 7, 2026
The Blue brands give local recognition and access to an established national network. That can help win and retain employers, but the company does not disclose a retention rate that separates brand strength from price and network breadth.
Medical membership fell to 44.949m from 45.621m a year earlier and a commercial fee-based customer left; the Blue name has not prevented customer and government-member attrition.
- Medical members44,882,000-1%
- Benefit expense ratio90.6%-0.7 pts
- Negative publicity around insurers or prior authorization practices
- Service quality issues impacting member/employer perception
- Competitors increasing marketing spend and brand investment
- FilingElevance Health Form 10-K (FY ended 2025-12-31)Feb 6, 2026
- Applies to
- CarelonRx
- Confidence
- Durability
- medium
- Trajectory
- narrowingas of Oct 7, 2026
Replacing claims adjudication, formulary data, pharmacy networks and member services requires a coordinated payer transition. These switching costs are real but moderate; prescription volume fell in 2026 and CarelonRx depends on Caremark for core services.
Adjusted prescriptions fell to 80.9m from 83.3m a year earlier; workflow integration has not prevented volume loss, although the filing does not isolate client churn.
- Adjusted prescriptions82,600,000-3%
- Standardized APIs and data portability reduce integration frictions
- Clients carve out specialty pharmacy or point solutions
- New entrants offering tech-first PBM administration
- Applies to
- CarelonRx
- Confidence
- Durability
- medium
- Trajectory
- stableas of Oct 7, 2026
Distribution advantage from selling PBM services to Elevance-affiliated health plans plus external clients; supports cross-sell with medical and other Carelon services.
FY2025 CarelonRx affiliated revenue was $18.917bn and external revenue $24.483bn; the internal channel remains substantial, but Q2 scripts fell to 80.9m and external growth remains contested.
- Adjusted prescriptions82,600,000-3%
- Purchasers push for best-of-breed vendors and unbundle PBM
- Regulatory constraints on tying/bundling
- Competitors bundle PBM + medical + services at larger scale
- Applies to
- Carelon Services
- Confidence
- Durability
- medium
- Trajectory
- narrowingas of Oct 7, 2026
Care management, utilization review and provider data are integrated into payer operations, which makes replacement harder. Protection is limited: a care-delivery contract was reduced and modified in 2026, and external revenue fell sharply.
Carelon Services external revenue fell to $1.040bn from $2.095bn after contract changes, and consumers served fell to 92.4m from 97.3m; integration did not protect all contracts.
- Carelon Services consumers91,000,000-7%
- Data sharing restrictions and privacy regulation
- Competitors with larger datasets and provider footprints
- Analytics tooling commoditization (AI/automation)
Profile change log
- Nov 11, 2026 · business change
Elevance reaffirmed its 2026 EPS floors of $22.00 GAAP and $29.00 adjusted on November 10, with benefit expense ratio guidance of 90.2% plus or minus 50 basis points. This is a forecast, not a realized underwriting result. Source: https://www.sec.gov/Archives/edgar/data/1156039/000115603926000074/elv-20261110.htm
- Nov 11, 2026 · analyst revision
Reconciled current-quarter operating evidence and guidance; added the latest demand and capital-allocation counterevidence without changing moat strength ratings.
- Oct 7, 2026 · analyst revision
Replaced Q2 segment revenue weights with FY2025 external revenue and removed profit shares that excluded corporate costs. Reduced Blue license strength from 5 to 4 because rights protect brand use rather than the insurance market. Added trajectories, operating evidence, management and a balanced debate.
- Oct 7, 2026 · business change
Elevance announced its 2027 Medicare Advantage offerings, keeping local brands and coordinated services as its enrollment proposition for the new plan year.
- Oct 7, 2026 · business change
Elevance reaffirmed full-year earnings and medical-cost guidance, leaving the expected recovery dependent on premium repricing and claims performance.
- Oct 7, 2026 · business change
CMS closed the risk-adjustment enforcement process after required data corrections; the threatened sanctions were not imposed, but repayment obligations remained.
- Oct 7, 2026 · business change
Elevance appointed new government-business and Carelon leaders to improve clinical execution, financial oversight and coordination with the health plans.
- Oct 7, 2026 · business change
CMS threatened Medicare Advantage enrollment and marketing sanctions over historical risk-adjustment data, creating a remediation requirement and repayment exposure.
- Oct 7, 2026 · business change
The Blue provider antitrust settlement took effect, requiring payments and changes to provider contracting, prompt payment and BlueCard technology.
- Oct 7, 2026 · business change
Selected large national employers gained a second Blue plan bid under the subscriber antitrust settlement, increasing competition within the Blue system.
- Oct 7, 2026 · business change
Elevance bought CareBridge, extending Carelon’s home and community-based care for Medicaid and dual-eligible members.
- Oct 7, 2026 · business change
Elevance invested $2.580bn in Mosaic Health with Clayton, Dubilier & Rice, creating a minority partnership for care delivery and provider enablement.
- Oct 7, 2026 · business change
Elevance bought Paragon Healthcare, adding infusion centers and specialty pharmacy services to CarelonRx.
Industry & peers
Peer map
U.S. health insurance and managed care
Medical insurance and administration for employer, individual, Medicare Advantage and Medicaid plans in the United States, including access to provider networks and self-funded employer administration. Excludes pharmacy benefit management sold separately, life insurance and providers’ own care-delivery revenue.
- UnitedHealth Group
- Elevance Health
- Humana
- Centene
| Stocks | Moat | Gross m. | Op. m. | |
|---|---|---|---|---|
| ELV | 77 | – | 2.4% | |
| Industry median | 5 | 77 | – | – |
| Sector median | 55 | 76 | 61.5% | 17.3% |
| All stocks median | 398 | 76 | 53.1% | 20.0% |
Moat medians cover every stock. Margin medians count only stocks with collected numbers and need at least three.
Drivers & risks
- Annual premium repricing can offset higher hospital, physician and drug costs; state Medicaid rates may catch up more slowly than commercial premiums.
- Aging expands Medicare demand, while eligibility reviews and coverage rules determine Medicaid enrollment and the risk mix.
- Employers buy network breadth, administration and total cost, so local provider relationships matter even when national carrier names are well known.
- Higher interest rates can improve income on insurer investments, while changes in bond values and investment returns can obscure health-plan profit. Domestic U.S. premiums create little direct currency exposure.
- Medical utilization and provider-price inflation can outrun annual pricing; losses can persist even when premium revenue rises.
- Reduced subsidies or stricter Medicaid eligibility can remove healthier members and worsen the remaining risk pool.
- Medicare coding audits, repayment demands and quality ratings change reimbursements and can restrict new enrollment.
- Local concentration attracts antitrust intervention; second Blue bids and provider settlement requirements reduce incumbent protections.
- A weak labor market reduces employer enrollment and shifts people between employer coverage, exchanges and Medicaid.
Bulls & bears
Can premium repricing and Carelon cost control rebuild underlying profit while retaining members and external clients, after medical inflation and Medicare repayment costs?
Arguments
What to watch
- 1Benefit expense ratio and Health Benefits operating gain
- 2Medical members and CarelonRx adjusted prescriptions
- 3Carelon Services external revenue, consumers served and operating gain
- 4CMS repayment liability and parent cash available for dividends
Next check: Next reported quarter and subsequent issuer announcements: Benefit expense ratio, membership and earnings excluding non-operating items. The next release date is not inferred from the prior reporting calendar.
Sources: company filings and dated sources collected for Find My Moat; market cap as of Nov 10, 2026. Not investment advice.
Free to reuse, commercially too, with a credit link. See the data license.
Moat Score 77/100 by <a href="https://www.findmymoat.com/stocks/XNYS:ELV">Find My Moat</a> (as of September 2026)Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.